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Summary.-Enhancement of CCNU cytotoxicity by misonidazole (MISO) was
studied in three tumours and two normal tissues in the mouse.
The 3 experimental tumours (SCCVII/St, EMT6 and KHT) showed very
different sensitivities to CCNU alone, but MISO enhanced the cell killing in ech case.
The effect was not always dose-modifying, so that the CCNU dose range for the great-
est enhancement was different in each of the tumours. In all 3 tumours, enhancement
increased with dose of MISO.
The effect on two normal tissues, marrow (CFU-S) and testis (spermatogonia), was
also investigated. Enhancement of marrow toxicity could be demonstrated only at
CCNU doses > 12 5 mg/kg, so that at lower CCNU doses there was a therapeutic gain
equal to the tumour enhancement ratio. The spermatogonia effect, however, showed
enhancement by MISO similar to that seen in the tumours at all CCNU doses up to
20 mg/kg.
ENHANCEMENT OF THE CYTOTOXICITY of
alkylating agents by misonidazole (1-[2-
nitromidazole-1 -yl] - 3-methoxypropan -2-
ol) (MISO) has been reported for several
mouse tumour systems by many authors
(Rose et al., 1980; Tannock, 1980; Clement
et al., 1980; Martin et al., 1981; Law et al.,
1981; Siemann, 1981; Stephens etal., 1981;
Twentyman et al., 1981; AMulcahy et al.,
1981). Most of these studies have shown
that, at least under some circumstances,
MISO is more effective in increasing the
cytotoxicity of chemotherapeutic agents
to tumours than to normal tissues, thereby
giving a positive therapeutic gain, though
there is no clear consensus as to the
mechanisms involved.
Particularly dramatic enhancement has
been reported for the combination of the
nitrosourea CCNU (1-[2-chloroethyl]-3-
cyclohexyl-1-nitrosourea) and MISO in the
KHT sarcoma (Siemann, 1981). An en-
hancement of up to 2-4 was obtained,
which, compared with a value of 1-4 for
normal-tissue toxicity assessed by the
LD50/30 assay, leads to a "therapeutic
gain" of 1-7-1 8.
An aim of the experiments described
here was to determine whether this
encouraging result could be obtained in
other tumours, and whether the low
enhancement of normal-tissue toxicity
holds when more specific and clinically
relevant end-points than LD50/30 are
used.
The principal dose-limiting toxicity of
CCNU in man is delayed leucopenia due to
the killing of marrow stem cells. However,
following the use of CCNU in the treat-
ment of the more curable cancers such as
Hodgkin's disease, an otherwise successful
outcome is often complicated by long-term
sterility in male patients. The responses of
marrow stem cells and testis were, there-
fore, selected as clinically relevant end-
points for the assessment of normal-tissue
in the present study.
MATERIALS AND METHODS
Tumour systems
Three mouse tumour lines were used in the
present experiments: EMT6/St/lu tumour
(Brown & Workman, 1980), the SCCVJI/St
carcinoma and the KHT sarcoma (Kallman etD. G. HIRST, J. M. BROWN AND J. L. HAZLEHURST
al., 1967). The SCCVII/St tumour is a
squamous carcinoma which arose spontane-
ously in the abdominal wall ofa C3H mouse in
the laboratory of Dr H. Suit, Massachusetts
General Hospital Boston, and was subse-
quently adapted for clonogenic growth by Dr
K. Fu, Dept of Radiation Oncology, Univer-
sity ofCalifornia SanFrancisco. Each ofthe 3
tumour-cell lines was maintained by passage
in vitro and as solid tumours in syngeneic
mice: BALB/c for EMT6/St/lu and C3H/Km
for SCCVII/St and KHT tumours. For each of
the tumour lines, 2 x 105 cells in a volume of
0 05 ml were inoculated s.c. (SCCVII/St and
KHT) or intradermally (EMT6) in the flank.
Animals were treated with drugs when their
tumours were in the range 300-900 mg. In
most experiments tumours were excised
24 h after CCNU injection, though this
interval was varied in some experiments in
order to study the development or repair of
drug-induced cell damage. Three to 5 tumours
were used for each data point. Tumours were
minced by high-speed chopping, and disaggre-
gated with an enzyme cocktail of 0.05%/o
pronase, 0-020% DNAse and 0-015% collagen-
ase in Hanks' buffered salt solution (HBSS).
The resulting cell suspensions were filtered
through a fine, stainless-steel screeil (100jum
mesh) and the density of viable cells
determined by counting in a haemacytometer
the number of cells which excluded trypan
blue. Cells were suspended in medium and
plated in Petri dishes at 3 predetermined
dilutions per group. Eagle's medium plus 10%
fetal calf serum was used for SCCVII/St
tumours, Eagle's plus 12-5% horse serum and
2.5% fetal calf serum for KHT, and
Waymouth's medium plus 10% fetal calf
serum for EMT6. After 12-14 days' incuba-
tion at 37°C the number ofcolonies with > 50
cells were counted and the plating efficiency
(PE) calculated. Surviving fractions were
determined by expressing the PEs of
treated groups as a fraction of the PE of
tumour cells from animals injected with
solvents only.
Normal-tissue studies
Marrow.-To determine the toxicity of
treatments to marrow stem cells, the spleen-
colony assay of Till & McCulloch (1961) was
used. Femurs of drug-treated animals were
excised and flushed with 0 5 ml of HBSS at
4°C. Four or 5 animals were used for each
data point. Cells were checked for viability by
trypan-blue exclusion and, depending on the
expected level of survival, an appropriate
number of cells were injected into the tail
veins of 6-8 recipient animals preirradiated
with 7-5 Gy whole body. The cloning effici-
ency of the cells was determined from the
mean number of colonies per spleen at 7-8
days after injection. Spleens of irradiated
animals receiving no marrow cells were
excised to determine the number of endo-
genous colonies. In most experiments none
were found but in no experiment was the
incidence greater than 0 3 colonies per spleen.
Testis.-The cell-cycle kinetics ofspermato-
genesis in the mouse testis have been studied
extensively (Oakberg, 1956; Meistrich et al.,
1978). While the response of spermatogonial
stem cells will determine long-term sterility,
this population in the testis of the mouse
shows considerable resistance to most chemo-
therapeutic agents. The survival of the more
sensitive differentiated spermatogonia was
therefore used as an end-point in the present
study. It has been shown (Lu & Meistrich,
1979) that the number ofsperm heads in testis
homogenates 29 days after drug treatment
reflects the sensitivity ofdifferentiated sperm-
atogonia to that treatment. The same
technique was used in the present experi-
ments except that the testis homogenates
were not sonicated before sperm-head count-
ing, because excellent reproducibility has
been obtained without this procedure.
Drug treatments
All drug solutions for injection were pre-
pared immediately before injection. Misonida-
zole(MISO)andSR-2508(N-(2-hydroxyethyl)-
2-(2-nitro-1-imidazolyl)acetamide) were dis-
solved in sterile saline at a concentration of
25 mg/ml and 80 mg/ml, respectively, in most
experiments. CCNU was dissolved in peanut
oil (Eastman Kodak) at concentrations of 1, 2
or 4 mg/ml, depending on the drug dose to be
administered. MISO and CCNU were injected
i.p., whereas SR-2508 was injected into a tail
vain. In experiments requiring "simultane-
ous" injection ofMISO and CCNU, MISO was
always given immediaely before CCNU into
the opposite side of the abdomen.
RESULTS
Tumours
CCNU dose responses.-Previously pub-
lished data (Siemann, 1981) have shown
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FIG. 1.-Survival of the cells of 3 mouse tumours after simultaneous injections of saline and CCNU
(cO) or MISO (750 mg/kg) and CCNU (0). Tumours were excised 24 h after drug injection. Each
panel shows data from 2 or more experiments. Lines drawn by eye.
dramaticenhancement ofCCNUtoxicityto
tumourswhen MISO and CCNU were given
simultaneously. The first experiments in
the present series therefore also used
simultaneous administration of the 2
agents. Fig. 1 shows the effect ofCCNU on
the in vitro survival of SCCVII/St, EMT6
and KHT tumour cells after drug treat-
ment in vivo. Cell survival decreased with
increasing dose of CCNU, but the sensi-
tivities of the 3 tumours were grossly
different. In each ofthe tumours, however,
simultaneous administration of 750 mg/kg
MISO considerably reduced cell survival.
In the case ofKHT and SCCVII/St, MISO
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appeared to be dose-modifying within the
experimental range, giving enhancement
ratios of 1'7-1 8. IN the case ofEMT6, the
data are more consistent with removal of
the rather larger "shoulder." When an
interval of 1 h was allowed between MISO
and CCNU injections, the results were not
significantly different from those obtained
with simultaneous injection (data not
shown).
Effect of MISO dose.-The relationship
between MISO dose and cell survival at a
constant dose of CCNU is shown for the 3
tumour lines in Fig. 2. Drugs were given
simultaneously. In each case tumour-cell
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FIG. 2.-The relationship between cell survival and MISO dose for 3 mouse tumours at a constant
close of CCNU (20 mg/kg in EMT6 and SCCVII/St; 5 mg/g in KHT). Also shown is the effect of the
hiighest MISO dose in oil solvent only (f). Drugs given simultaneously. Line was drawnbyeye.
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FIG. 3.-Dose-response curves for marrow (a,
b) and spermatogonia (c, d) after treatment
with saline+CCNU (O) or 1IISO (750 mg/
kg) plus CCNU (0). Drugs were given
either simultaneously (a, c) or AIISO 1 h
before CCNU (b, d). Lines were (irawn by
eye. Each point shows pooled data from
4-7 animals, a and c inclu(de (lata from 3
separate experiments.
survival appeared to decrease progres-
sively as the dose of AIISO was increased,
over the range 125-1000 mg/kg, though
enhancement w%Aas minimal at doses below
500 mg/kg.
Normal tissues
The effects of MISO on the CCNU
dose-response curves for the two normal
tissues are shown in Fig. 3. In the case of
marrow stem cells (Fig. 3a, b) AIISO
enhanced the cytotoxicity of CCNU,
whether administered simultaneously or
1 h before. However, this effect was seen
only at CCNU doses > 12 5 mg/kg; MISO
had no significant effect at lower doses.
The number ofsperm heads per testis 29
days after various doses of CCNU with or
without MISO is shown in Fig. 3c, d. An
effect of MISO was seen at all doses up to
20 mg/kg. An effect of MISO was seen at
all doses up to 20 mg/kg. At higher doses,
MISO did not reduce the nuimber ofsperm
heads further. The apparent "bottoming"
ofthe dose-response curves at 105 sperm
heads/testis may be an artefact of the
technique, due to a small number of cells
in a more resistant stage of spermato-
genesis when the drugs were given (see
Meistrich et al., 1978). This explanation is
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FIG. 4.-Relationship between MISO dose and killing of marrow stem cells and spermatogoilia
at a constant dose of CCNU (20 mg/kg). Lines drawn by eye. Also shIowni are spernm per control
testic (O) and with MISO alone (-). Each marrow point, is the mean of 2 groups of 6 animals.
Sperm-head for 6 animals per point.
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FIG. 5.-Survival of KHT tumour cells after
simultaneous injection ofSR-2508 (800 mg/
kg) and CCNTU (OI) or saline and CCNU
(*). The line is drawn through the saline
and CCNU data by eye.
supported by the observation that spread-
ing the drug injections over a few days
gives linear curves to lower levels (data not
shown). Data at CCNU dose levels of
20 mg/kg or less were used in estimating
enhancement ratios. ERs of 1 7-1 8 were
obtained for simultaneous injections and
1*5-1*6 when MISO was given 1 h before
CCNU.
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The effect ofMISO dose on marrow stem
cells and testis spermatogonia at a con-
stantsimultaneous dose of CCNUis shown
in Fig. 4. As the dose of MISO increased,
progressively more enhancement ofCCNU
cytotoxicity was found. This relationship
is very similar to that for the tumours.
Mechanisms
In our previous study of the enhance-
ment of cyclophosphamide cytotoxicity
by MISO (Law et al., 1981) metabolic
effects were excluded as the principal
mechanism ofinteraction. We have tested
the possible importance of an effect of
MISO on CCNU metabolism and pharma-
cokinetics in the following experiments.
The effect of SR-2508 on CCNU cyto-
toxicity was investigated. The radio-
sensitizer SR-2508, a 2-nitroimidazole of
similar electron affinity and radiosensi-
tizing efficiency to MISO (Brown et al.,
1981) is less toxic and not appreciably
metabolized in vivo (Workman & Brown,
1981). Furthermore, it does not cause a
drop in body temperature, as seen in mice
after MISO (Law et al., 1981). Fig. 5 shows
the effect ofSR-2508 on cell survival after
CCNU in the KHT tumour. SR-2508 did
not enhance the cytotoxicity of CCNU.
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FIG. 6.-Effect of time from drug injection to tumour excision on cell survival. CCNU doses were
either 20 mg/kg (SCCVII/St and EMT6) or 5 mg/kg (KHT) and given simultaneously with
either 750 mg/kg MISO (0*) or saline (0). The effect ofMISO combined with solvent is also shown
(-), and presents the means of 2 experiments.
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MISO are apparent/ in each case. The
pattern is similar to that in SCCVII/St
tumours.
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I'he grea.t differences in sensitivity of
Z the\ ' ese tunmours to CCNU reflects the >>lo-l_ diversit of clinical response to most a ~~~~chemotherapeutic agents. CCNU has
L shown useful activity in a limited number
0-2 of tumour sites (see W;\asserman et al.,
o 8 16 24 1974, for review).
HOURS BETWEEN INJECTION AND EXCISION in our experimental tumours
FI-. 7. Effect of time from (1rug injection to two principal questions relating to the
marrowx removal on (ell survival after effect MISSO either simultaneous 750 mg/kg MISO + can MISO enhance the cell killing in
20mg/kg CCNU U) or saline + 20
kg CCNU (O,L). ata pooled from 2 resistant tumour which could
experiments. The results in (b) wsere broaden clinical usefulness obtained
12 months after those in (a) d,
secondl cvtotoxicitv in tumours an(l show more resistance to(CNU. an y, iS y sensitive to CCNU sufficiently enhanced by
When pentobarbitone sodium (50 mg/ MISO cure without signifi-
kg) was given simultaneously with CCNU, cantly affecting normal-tissuie toxicity?
no enhanced toxicity was seen in the The answer each case would
EMT6 tumour (data not shown) though "No", of ISC and
this treatment lowered the body tempera- CCNU. ttumour 1)
ture of the animals by 7°C. was so resistant to CCNU that large doses
Experiments were carried out to investi- were required show anv and
gate the involvement of repair processes in although addition MISO
the mechanism of enhancement of CCON! considerable this was seen
toxicity. Data were obtained for the 3 only
experimental tumours SCCVII/St, EMT6 where consider-
an(1 KHT. The pattern of cell survival ably other
from tumours excised at different times hand, tutmottr c)
after drug injection is shown in Fig. 6. In showed
the SCCVII/St tumour (Fig. 6a) cell including low-dose
survival after CCNU decreased between did
and 24 h, but reached a constant level by tumour
6 h in EMT6 (Fig. 6b). In case of KHT doses
(Fig. 6c) survival first fell and then repeated however,
recovered slightly. Simultaneous MISC fractionated
enhanced the toxicity at all but the possible
earliest time intervals, increase
The results of similar experiments to The therapeuitic
determine marrow stem-cell survival at should doses
various times after drug injection are (excepting
shown in Fig. 7. Although the sensitivity same
of the marrow to CCNU alone was less in a of MISC)
later experiment (Fig. 7b) than when al., proposedl carried out year before (Fig. 7a), the that by MIISC
progressive decline in cell survival with through
time up to 12 h and the enhancement by tially was,
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however, little indication ofrecovery after
CCNU, at least in the 24 h immediately
after drug injection (Fig. 7). Only in the
KHT tumour was there any increase in
survival, but even then survival decreased
with time after injection up to 6 h.
However, there results should not be
interpreted as excluding the possibility of
PLD repair. Some repair may occur which
is masked by the declining survival.
As shown in Fig. 6, the dominant trend
was for survival to decrease as the interval
between injection of drug and tumour
excision was increased. This effect might
reasonably be attributed to continued cell
killing by CCNU metabolites remaining in
the circulation of the aniimal; enhance-
ment by MISO would then reflect an effect
on CCNU metabolism which increases the
yield of toxic species. This view was
reinforced by the observation that the
radiosensitizer SR-2508 had no effect on
the sensitivity of the KHT tumour to
CCNU (Fig. 5). SR-2508 is similar to MISO
in its sensitizing efficiency and electron
affinity (Brown et al., 1981), but unlike
MISO it is not extensively metabolized in
vivo. The lack of effect of SR-2508 might
suggest that metabolism of the radio-
sensitizer is necessary for chemosensitiza-
tion, but it does not exclude other
mechanisms.
There is evidence from other studies to
suggest that another explanation ofMISO
enhancement of CCNU toxicity may be
more attractive. Decreasing survival has
been shown to occur over several hours
after a 1h exposure of mammalian cell in
vitro to CCNU and subsequent removal of
the drug (Barranco et al., 1975). It seems
reasonable to infer that decreasing sur-
vival would occur in vivo by a similar
mechanism not requiring the presence of
the drug or its metabolites. Some insight
into the nature of this process is provided
by Ewig & Kohn (1978). Alkaline elution
experiments have shown that cross-links
are formed between opposing strands of
the DNA of cells treated with CCNU, and
that this process occurs slowly over several
hours, even after the drug has been
removed. These results are entirely con-
sistent with our own observations of the
slow development of lethal lesions in
tumour cells treated in vivo with CCNU.
Experiments are now in progress, using
the alkaline-elution assay, to determine
whether MISO increases the yield of these
DNA cross-links or inhibits the systems
responsible for their repair.
CONCLUSIONS
1. Mouse tumours show great differences
in their sensitivity to CCNU.
2. In all the tumoursinvestigated, MISO
enhanced CCNU cytotoxicity.
3. The resistanttumourshowed enhance-
ment only at high doses where the dose-
limiting normal tissue was equally sensi-
tized.
4. Sensitive tumours showed enhance-
ment at lower CCNU doses where there
was no sensitization by MISO of the
cytotoxicity to marrow stem cells.
5. If sterility is considered to be
an important factor in the treatment
outcome, it should be noted that sperm-
atogonia were sensitized by MISO almost
as much as the tumours, at all CCNU
doses.
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